Replimune Group (NASDAQ:REPL) Insider Konstantinos Xynos Sells 7,248 Shares

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,248 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the completion of the sale, the insider owned 139,685 shares in the company, valued at $1,271,133.50. The trade was a 4.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Replimune Group Stock Up 1.6%

Shares of REPL traded up $0.15 during mid-day trading on Thursday, hitting $9.14. 254,651 shares of the company’s stock were exchanged, compared to its average volume of 4,370,007. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $17.00. The company has a market cap of $716.55 million, a PE ratio of -2.65 and a beta of 0.80. The company has a 50-day simple moving average of $6.62 and a 200 day simple moving average of $7.40.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on REPL. Barclays downgraded Replimune Group from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Monday, October 20th. BMO Capital Markets cut Replimune Group from an “outperform” rating to an “underperform” rating and dropped their price objective for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $3.00 to $13.00 in a report on Monday, October 20th. Finally, Cantor Fitzgerald raised shares of Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after purchasing an additional 7,569 shares during the period. US Bancorp DE lifted its stake in shares of Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after buying an additional 3,921 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares during the period. Raymond James Financial Inc. acquired a new position in Replimune Group in the 2nd quarter valued at about $69,000. Finally, GSA Capital Partners LLP bought a new position in Replimune Group in the 3rd quarter valued at about $81,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.